{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-292625","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2022-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.857497+00:00","generated_at":"2026-06-21T12:59:03.727388+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaccinex raises $3.8M via private placement of 7.14M shares at $0.5293 per share","bullets":["Issued 7,142,496 shares to accredited investors for gross proceeds of ~$3.8 million.","Insider participation: CEO Maurice Zauderer, chairman Albert Friedberg, directors Jacob Frieberg and Gerald Van Strydonck.","Proceeds to fund pepinemab clinical trials and for working capital.","Registration rights agreement filed to register shares for resale within 75 days after closing.","Shares sold under Section 4(a)(2) and Rule 506 of Regulation D."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-292625","json":"https://secwatch.observer/filing/0001193125-22-292625.json","markdown":"https://secwatch.observer/filing/0001193125-22-292625.md","text":"https://secwatch.observer/filing/0001193125-22-292625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/0001193125-22-292625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/d391207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:59:03.727388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72d7b8efd938f292d1bc8e012f1c4ce9b0f25b6b","claim":"VACCINEX, INC. entered into Registration Rights Agreement with certain of the Investors (effective 2022-11-22).","evidence_excerpt":"On November 22, 2022, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with certain of the Investors that affords such Investors certain registration rights with respect to the Shares.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/0001193125-22-292625-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain of the Investors"},{"label":"Effective","value":"2022-11-22"}],"fact_type":"material_agreement"},{"claim_id":"de2d30ece775d73d27d6662e921cf2157fdaa2c1","claim":"VACCINEX, INC. entered into Stock Purchase Agreement with the investors named therein valued at approximately $3.8 million (effective 2022-11-18).","evidence_excerpt":"On November 18, 2022, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the investors named therein an aggregate of 6,112,031 shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), at a purchase price of $0.5293 per Share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1205922/000119312522292625/0001193125-22-292625-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors named therein"},{"label":"Value","value":"approximately $3.8 million"},{"label":"Effective","value":"2022-11-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}